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Abstract
Background: Lateral epicondylitis is a painful condition responsible for loss of function and sick
leave for long periods of time. In many countries, the treatment guidelines recommend a wait-and-
see policy, reflecting that no conclusions on the best treatment can be drawn from the available
research, published studies and meta-analyses.
Methods/Design: Randomized double blind controlled clinical trial in a primary care setting.
While earlier trials have either compared corticosteroid injections to physical therapy or to
naproxen orally, we will compare the clinical effect of physiotherapy alone or physiotherapy
combined with corticosteroid injection in the initial treatment of acute tennis elbow. Patients
seeing their general practitioner with lateral elbow pain of recent onset will be randomised to one
of three interventions: 1: physiotherapy, corticosteroid injection and naproxen or 2: physiotherapy,
placebo injection and naproxen or 3: wait and see treatment with naproxen alone. Treatment and
assessments are done by two different doctors, and the contents of the injection is unknown to
both the treating doctor and patient. The primary outcome measure is the patient's evaluation of
improvement after 6, 12, 26 and 52 weeks. Secondary outcome measures are pain, function and
severity of main complaint, pain-free grip strength, maximal grip strength, pressure-pain threshold,
the patient's satisfaction with the treatment and duration of sick leave.
Conclusion: This article describes a randomized, double blind, controlled clinical trial with a one
year follow up to investigate the effects of adding steroid injections to physiotherapy in acute lateral
epicondylitis.
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Lateral epicondylitis of the elbow is characterised by pain
and tenderness of the lateral humeral epicondyle and pain
on resisted dorsiflexion of the wrist, the 3. digit or both.
There is also often pain on resisted radial deviation of the
wrist. The condition is a frequent complaint with an over-
all prevalence of 1-3% [1]. The highest incidence is found
in persons 40-60 years old. For women, the incidence
increases to 10% between the ages of 42 - 46 [2,3]. The
incidence in general practice is estimated to be 4 - 7 per
1000 per year [2,4,5]. The aetiology has been assumed to
be over-use damage to the forearm extensor muscles -
either minor or non - recognised traumas. There is little
evidence of inflammation [6]. Most authors attribute the
condition to a lesion in the extensor apparatus at the lat-
eral humeral epicondyle, specifically the short radial
extensor muscle [2,7]. Cyriax [8] and Ombregt et al [9]
identify four subgroups of lateral epicondylitis depending
on the exact location of the lesion. In their experience, in
90% of the cases, the lesion is situated in the anterior part
of the lateral epicondyle at the origin of the short radial
extensor muscle. The second most frequent lesion
accounts for 8% of the cases and is localised at the muscle
body itself. Lateral epicondylitis usually is a self-limiting
condition, but complaints may last up to 2 years or longer
[10]. A study from general practice shows that 80% heal
within one year on wait-and-see treatment (rest, paraceta-
mol or NSAIDs taken orally) even when initial symptoms
had lasted more than 4 weeks [11]. In many countries,
treatment guidelines recommend a wait-and-see policy.
Many treatments have been proposed leading to a
number of trials, but reviews including several recent
meta-analyses have led to no conclusions as to which is
the best. This is due to low statistical strength, low internal
validity and insufficient study data reporting [12,13].
Schmidt et al 2003 [14] reviewed literature on physical
therapy prior to 1999 and found no evidence of effect,
with the exception of ultrasound, where a minor effect
was shown. Bisset et al 2005 [15] published a meta-analy-
sis of 28 randomised studies published before 2003 of dif-
ferent physical therapies for lateral epicondylitis satisfying
at least 15 out of 28 criteria (PEDro rating scale)[16]. Most
studies had a small number of subjects, and only eight
had long term follow-up of effect of therapy. Extra corpo-
real shock wave therapy was found to have no effect, and
manipulation and exercise were found to have only a
short-term effect.
A meta-analysis by Smith et al 2002 [17] on the effect of
corticosteroid injections found evidence of short-term
pain relief, but no effect beyond the initial 6 weeks. There
was however some uncertainty due to few and small stud-
ies.
The Cochrane Library has several reviews of treatment for
lateral epicondylitis: acupuncture [18], deep transverse
friction massage [19], NSAIDS [20], orthosis [21], extra
corporeal shock wave therapy [22] and surgery [23]. These
reviews all conclude that there is insufficient evidence to
draw firm conclusions as to which methods of treatment
are effective. However, there are indications that topical
NSAIDs and manipulation and exercise have a short term
effect. As to NSAIDs taken orally, there is probably a short-
term effect, although it is impossible to either recommend
use or not. For extracorporeal shockwave therapy, there is
evidence to conclude that this treatment has no effect.
Ultrasound has a possible short-term effect based on one
meta-analysis [14]. In fact, there is scant support for any
long-term treatment in the literature.
Looking for a better treatment for epicondylitis, we have
found two studies to be of special interest. Both were car-
ried out in primary care settings with one year follow-up.
One study compared corticosteroid injection with physi-
cal therapy (ultrasound, manipulation and exercise) and
a wait-and-see group [11]. The other compared corticos-
teroid injection with naproxen orally and placebo medi-
cation [24]. Both concluded that corticosteroid injection
is safe and effective for pain relief during the first 6 weeks,
and the effect of this treatment is better than physiother-
apy, wait-and-see and naproxen orally within the same
time-frame. Smidt et al [11] found that physiotherapy
gave some, but not significantly better long-term effect
than wait-and-see treatment. A more recent study compar-
ing physiotherapy and corticosteroid injection [25] con-
cluded that the significant short term benefits of
corticosteroid injection are paradoxically reversed after six
weeks, with high recurrence rates and that combining
elbow manipulation and exercise has superior benefit to
wait and see in the first six weeks and to corticosteroid
injections after six weeks. Comparing corticosteroid injec-
tion with placebo injection, four clinical trials found no
significant effect of corticosteroids at 6 months [26-29]
and at 12 months, although one trial reported improve-
ment at 8 weeks [27].
We find there is a good reason to investigate the long-term
effects of physiotherapy - this is also recommended in a
recent meta-analysis [15]. At the same time, it would be
interesting to see whether the good initial response from
corticosteroid injection [11,24] may be extended if com-
bined with physiotherapy. We have only found two stud-
ies that have evaluated this combination, one found no
added effect of corticosteroid injection at 6 months [28],
the other had only a 7 week follow up [30]. A protocol for
a larger study has recently been published [31].Page 2 of 8
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The objective of this study is to compare the clinical effect
of physiotherapy alone or physiotherapy combined with
corticosteroid injection in the initial treatment of acute
lateral epicondylitis in a primary care setting. Also, to find
the short and long term effect of physiotherapy and to
ascertain whether this outcome is influenced by corticos-
teroid injection.
Methods and design
The study is designed as a randomized, placebo-control-
led trial in a primary care setting in the city of Sarpsborg
and surrounding areas in Ostfold county, Norway.
Patients are referred by their general practitioner to one of
two trial doctors who make the initial evaluation of inclu-
sion and exclusion criteria, as well as treatment, follow-up
and outcome assessments. After a treatment period of six
weeks, the patient is followed with assessments for a total
of 12 months.
Participants and recruitment
Patients aged 18-70 years seeing their general practitioner
with pain of recent onset from the lateral part of the elbow
are eligible for inclusion. The other inclusion criteria are
pain increase on resisted dorsiflexion of the wrist with the
elbow extended and the fingers flexed or pain increase on
resisted radial deviation of the wrist or resisted extension
of the third finger. We will investigate the acute condition,
and will exclude patients with a duration of complaints of
more than 3 months, as well as light, self-limiting condi-
tions with a duration of symptoms of less than two weeks.
We will exclude patients with tenderness located within
the muscle body itself (Cyriax type IV)[8]. Recent treat-
ment with corticosteroid injection or physiotherapy will
also exclude the patient. All exclusion criteria are given in
figure 1.
Intervention
In a six-week treatment period, patients will receive one of
three treatments:
• Physiotherapy, corticosteroid injection and
naproxen
• Physiotherapy, placebo injection and naproxen
• Wait-and-see treatment: naproxen alone
Injections
The injections will be blinded to the investigator and
given at start and after three weeks, consisting of triamci-
nolone 10 mg or placebo and lidocaine 10 mg (Triamci-
nolone: Kenacort-T® "Bristol-Myers Squibb" injection
solution 10 mg/ml ATC-no.: H02A B08. Placebo: Sodium
Chloride "B. Braun" injection solution 9 mg/ml ATC-no.:
V07A B-. Lidocaine: Xylocain® inj. "AstraZeneca" 20 mg/
ml ATC-no.: N01B B02). We have chosen to use triamci-
nolone since it has been used in earlier studies [11,24,25],
is readily available and commonly used. One study found
significant improvement with triamcinolone compared to
Exclusion criteriaFigure 1
Exclusion criteria.
Duration of complaints less than 2 weeks or more than 3 months
The tenderness is located within the muscle body itself in the proximal part of the short radial extensor muscle of the 
wrist (Cyriax type IV)
Treatment within the last 12 months for the same condition with corticosteroid injection or physiotherapy
Bilateral complaints
Previous surgical treatment for lateral epicondylitis
Deformities of the elbow (congenital or acquired)
Cervical radiculopathy or referred pain from neck or shoulder
Previous fractures or tendon ruptures in the elbow
Systemic musculoskeletal disease
Previous allergic reactions to corticosteroids or lidocaine
Contraindications to corticosteroids or NSAIDs:
        on-going or previous gastro-intestinal bleeding, previous ulcer or dyspepsia, severe asthma
        on-going systemic infection, local skin-infection, recently vaccinated with live virus, coagulopathies, SLE,
        severe liver- or kidney-disease, heart failure, diabetes, use of warfarin or NSAIDS
Pregnancy or breast-feeding
Fertile females not on effective birth control
Psycho-social or other reasons for not being able to participate throughout the studyPage 3 of 8
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and 20 mg triamcinolone [27]. The injection is given with
the patient in a supine position with the elbow flexed and
the wrist pronated. The skin is cleaned with alcohol and
the most tender point is located. A 0.6 mm needle is
inserted at 90 degrees down to the level of bone and then
pulled back 1-2 mm. The injection is done by leaving sev-
eral small depots at the surface of the tendon. After the
injection, the patient is tested for pain on resisted dorsi-
flexion of the wrist and the result recorded. The patient is
informed of possible adverse effects from the injection
and is advised to avoid pain provoking activities for the
rest of the day. After three weeks, possible adverse reac-
tions to the first injection will be recorded. Together with
possible increase of pain or symptoms, this is considered
before the decision to give a second injection is taken.
Physiotherapy
The physiotherapy will be given by two cooperating phys-
iotherapists twice weekly for six weeks. Based on treat-
ments used in earlier studies [11,25] a treatment protocol
has been devised comprising treatments that should be
well known by most physiotherapists. It will consist of
deep transverse friction massage at the tendon origin for
15 minutes, Mill's manipulation [9] once each treatment-
session and soft tissue treatment with stretching of the
radial wrist extensors. The patients will receive oral and
written instructions for home exercises daily for six weeks
with eccentric exercise (three times 30 repetitions) and
isolated stretching of radial wrist extensors (three times
daily for 40 seconds).
General treatment and information
All three treatment groups will receive naproxen 500 mg
twice daily for two weeks from start (Naprosyn Entero®
"Roche" 500 mg. ATC-no.: M01A E02). The reasons for
this are mostly pragmatic, since the use of NSAIDs is wide-
spread and the control group thus will receive some form
of treatment in the initial six-week period. The treatment
is expected to have uniform effect in the three groups.
Paracetamol can be taken for pain at the patient's own dis-
cretion up to 4 grams daily and use of such extra pain
medication will be registered. General advice will be given
to all groups, including the natural course of the condi-
tion, and expected duration of complaints is discussed.
Advice on avoiding pain-provoking use of the elbow is
given. The need for sick leave is discussed, but left for the
patient's own general practitioner to decide. Additional
treatment after the six-week treatment period is given at
the discretion of the patient's own general practitioner.
There are no restrictions as to what treatment the patient
can receive. Additional treatments will be registered on
the later assessments by the trial doctors.
Outcome measures and assessments
The primary outcome measure is the patient's evaluation
of improvement after 6, 12, 26 and 52 weeks [11]. Sec-
ondary outcome measures include pain, function and
severity of main complaint, pain-free grip strength, maxi-
mal grip strength, pressure-pain threshold, the patient's
satisfaction with the treatment, the need for co-interven-
tion and duration of sick leave.
All assessments are recorded using pre-made, standard-
ised forms. Outcome assessments are done by the trial
doctors and by the patient answering a questionnaire.
Based on earlier studies and assessment of the validity and
reliability of the outcome measures, the patient's evalua-
tion of improvement will be registered on a 6-point Likert
scale (much worse - worse - a little worse - some improve-
ment - much improvement - completely recovered) [11].
Elbow pain, to what extent the use of the elbow is affected
and severity of main complaint is registered on a Visual
Analogue Scale [11,24,32]. Pain-free grip strength and
maximum grip strength will be registered with a hand
held, analogue dynamometer as a mean of three measure-
ments in a ratio of affected to unaffected side (Jamar
Hydraulic Hand Dynamometer - 5030J) [32,33]. Pressure-
pain threshold over the epicondyle will be measured with
an analogue algometer, also as a mean of three measure-
ments in a ratio of affected to unaffected side. (Wagner
Instruments, Algometer FPK 20) [32,33]. Pain on resisted
dorsiflexion will be registered on a 3-point scale (none,
some, definite)[24]. Whether the patient experiences pain
on eight every-day activities (dressing, eating, washing,
household tasks, opening doors, carrying objects, with
work, at sports) will be registered using a pain-free func-
tion questionnaire [11,24].
Before start, a number of baseline characteristics will be
registered and an assessment will be done (figure 2). After
6, 12, 26 and 52 weeks, the following assessments will be
done: the patient's evaluation of improvement on a 6-
point Likert scale, treatment satisfaction (done only after
6 weeks on a 5-point Likert scale), days off work, type and
number of co-interventions (use of pain-killers, NSAIDs,
physiotherapy or corticosteroid injection), adverse reac-
tions or complications of the treatment (increased pain,
skin atrophy, gastro-intestinal reactions) and reasons for
loss to follow-up. In addition, the assessments done
before start will be repeated, registering elbow pain, to
what extent the use of the elbow is affected and the sever-
ity of main complaint, whether the patient experiences
pain during eight everyday activities, pain-free grip
strength and maximum grip strength, pressure-pain
threshold and pain on resisted dorsiflexion of the wrist
(figure 3).Page 4 of 8
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possible second injection if in the appropriate group.
Compliance to the naproxen treatment will be monitored
by counting remaining tablets. An overview of the study
design is given in figure 4.
Randomisation and blinding
A computerised randomisation schedule will be prepared
by an independent researcher, and using concealed alloca-
tion each patient will be assigned to one of three treat-
ments using numeric block randomisation. The patient
will first see one of the trial doctors, who is responsible for
inclusion, baseline assessment and treatment. This doctor
will not know the content of the injections, since these
will be prepared by a research assistant. The contents of
the syringe are covered by an opaque adhesive patch to
further disguise it. This way, the injections can be made
double blind for the doctor and patient. From week six,
the patient will see the other trial doctor, who will be una-
ware of which treatment the patient has received, and
patients will be cautioned at each assessment about not
disclosing what kind of initial treatment they received.
The assessments will thus be performed blinded. The suc-
cess of blinding will be assessed at 52 weeks by the trial
doctor guessing which treatment the patient received.
Sample size and statistical analysis
Sample size is based on the ability to detect a 25% differ-
ence in the success rate (defined as "much better" or
"completely recovered" on a 6-point Likert-scale) between
the groups at three months. Prior to three months, earlier
studies show a very large success rate on treatment with
corticosteroid injections[11,25]. Later in the course of the
condition, the success rate will increase regardless of inter-
vention. Based on earlier studies [11], we have assumed a
success rate of 55% at three months in the least successful
group. The target sample size is estimated at 52 patients
per group (two tailed α: 0.05, β: 0.20) giving a total of 156
patients. Assuming a loss-to-follow-up of 10% and practi-
calities in allocating the patients to 3 groups, we will
Baseline characteristics and assessment before startFigure 2
Baseline characteristics and assessment before start.
Baseline characteristics
Age
Gender
Patient still at work?
Manual labour ?
Duration of complaint in weeks
Daily pain last week?
Acute onset/gradual onset (days) of pain?
Dominant elbow affected?
Previous episode of lateral elbow pain?
Probable overuse, usual activity?
Probable overuse, unusual activity?
Patients preferred treatment. (physiotherapy, wait-and-see, corticosteroid injection, none preferred)?
Use of pain killers last week?
Other medical conditions (hypertension, diabetes...)
Assessment before start
Elbow pain registered on a VAS-scale (Visual Analogue Scale)
To what extent the use of the elbow is affected registered on a VAS-scale 
Severity of main complaint registered on a VAS-scale
Whether the patient experiences pain during eight everyday activities (dressing, eating, washing, household tasks, opening doors, 
carrying objects, at work, at sports) 
Pain free grip strength and maximum grip strength registered with a hand held dynamometer (mean of three measurements as 
ratio of affected to unaffected side)
Pressure-pain threshold over the epicondyle measured with an analogue algometer (mean of three measurements as ratio of 
affected to unaffected side)
3DLQRQUHVLVWHGGRUVLÀH[LRQRIWKHZULVWZLWKH[WHQGHGHOERZDQG¿QJHUVÀH[HGRUUHVLVWHGGRUVLÀH[LRQRIWKLUG¿QJHUPage 5 of 8
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patients. With an incidence of 4-7/1000 per year and
50.000 people living in the Sarpsborg area, we estimate a
period of inclusion of 1 to 1.5 years. The statistical analy-
sis will be based on intention-to-treat analysis.
Ethics and Data Security
The trial has been approved by The Regional Committee
for Research Ethics in Norway, The Norwegian Social Sci-
ence Data Services and The Norwegian Medicines Agency,
and all patients will be asked for written informed consent
on standardised forms. All patient data will be de-identi-
fied before use in research. The data will be kept de-iden-
tified on forms and in computers inaccessible to
unauthorised persons. The list linking each patient's name
and personal data will be kept separate, accessible only to
the two trial doctors. In compliance with government reg-
ulations, personal data will be kept de-identified for a fur-
ther period of 15 years after the end of the trial before
deletion.
Adverse reactions
Adverse reactions or side effects to naproxen, triamci-
nolone or physiotherapy would be grounds for dismissing
the patient from the trial. These factors will be continu-
ously appraised during the trial. Side effects to the treat-
ment with drugs will be reported in compliance with local
Norwegian law.
Discussion
Earlier studies, including meta-analyses, have concluded
that more research on treatment options for lateral epi-
condylitis is needed. Evidence based treatments guide-
lines will help in making effective and sound treatment
decisions. This study is designed to mirror the normal
work flow in a primary care setting, making the results
readily applicable in this setting. We have selected recent-
onset complaints as opposed to recurring or chronic
forms for easier comparison with earlier studies, and to
make the results more applicable in general practice,
where most patients with acute lateral epicondylitis are
seen. As to physiotherapy, we are cooperating with two
clinical physiotherapists engaged in normal practice, and
have developed a treatment protocol reflecting usual treat-
ments for this condition. By assessing the patients' time
off paid employment, we also hope to gain valuable
knowledge about the economic impacts of this condition.
To address the methodological problems in some earlier
Outcome measures after 6, 12, 26 and 52 weeksFigure 3
Outcome measures after 6, 12, 26 and 52 weeks.
The patient’s evaluation of improvement on a 6-point Likert scale 
Treatment satisfaction ( 5-point Likert scale - only registered at week 6)
Days off work
Type and number of co-interventions (use of pain-killers, NSAIDs, physiotherapy, corticosteroid injection)
Adverse reactions or complications of the treatment - increased pain, skin atrophy, gastro-intestinal reactions
Reasons for loss to follow-up
Elbow pain registered on VAS-scale (Visual Analogue Scale)
To what extent is the use of the elbow affected, registered on VAS-scale
Severity of main complaint, registered on VAS-scale
Whether the patient experiences pain on eight everyday activities (dressing, eating, washing, household tasks, opening
doors, carrying objects, with work, at sports)
Pain-free grip strength registered with hand held dynamometer . 
Maximum grip strength registered with hand held dynamometer. 
Pressure-pain threshold over the epicondyle measured with algometer
3DLQRQUHVLVWHGGRUVLÀH[LRQRIWKHZULVWZLWKH[WHQGHGHOERZDQG¿QJHUVÀH[HGRUUHVLVWHGGRUVLÀH[LRQRIWKLUG¿QJHU
Overview of the study designFigure 4
Overview of the study design. An overview of the study 
design showing recruitment, assessments, the three treat-
ment groups, follow-up and outcome assessments.
Patients with recent onset lateral elbow pain 
referred from their general practitioner
Screening by trial doctor
Included 
informed consent
Baseline assessment
Randomisation
General advice and naproxen 500 mg bid
Excluded 
did not meet 
eligibilty criteria
- did not wish to 
participate
Corticosteroid injection
Physiotherapy
(n=60)
Saline injection
Physiotherapy
(n=60)
Wait-and-see
(Control group) 
(n=60)
Corticosteroid injection
repeated at week 3
Saline injection
repeated at week 3
Encouragement
at week 3
Change of doctor
Assessment of outcome measures 
by blinded trial doctor at weeks 6, 12, 26 and 52Page 6 of 8
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randomised controlled study with a one year follow up.
An effort has been made to blind the injections to both
investigator and participant for more valid results. We
have calculated sample size and statistical strength as
shown above to produce valid results. The study will com-
ply with the CONSORT Statement [34] and the study pro-
tocol is published, enabling later comparison of what was
originally intended with what was actually done, thus pre-
venting both "data dredging" and post-hoc revisions of
study aims.
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